U.S. Federal Court Trial Over Takeda's Actos Opens In Louisiana
This article was originally published in PharmAsia News
Executive Summary
Opening arguments accused Takeda Pharmaceutical of hiding cancer risks of its Actos (pioglitazone) diabetes drug from patients and physicians. Takeda answered with a denial and a no-evidence assertion.